La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Athenex Gestione

Gestione criteri di controllo 4/4

Athenex's Il CEO è Johnson Lau, nominato in Jan2011, e ha un mandato di 12.75 anni. la retribuzione annua totale è $ 714.51K, composta da 73.5% di stipendio e 26.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 2.99% delle azioni della società, per un valore di $ 3.93K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.5 anni e 4.9 anni.

Informazioni chiave

Johnson Lau

Amministratore delegato

US$714.5k

Compenso totale

Percentuale dello stipendio del CEO	73.5%
Mandato del CEO	12.8yrs
Proprietà del CEO	3.0%
Durata media del management	4.5yrs
Durata media del Consiglio di amministrazione	4.9yrs

Aggiornamenti recenti sulla gestione

Recent updates

These Analysts Just Made A Sizeable Downgrade To Their Athenex, Inc. (NASDAQ:ATNX) EPS Forecasts

Mar 06

Have Insiders Been Buying Athenex, Inc. (NASDAQ:ATNX) Shares?

Feb 19

When Can We Expect A Profit From Athenex, Inc. (NASDAQ:ATNX)?

Jan 29

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Johnson Lau rispetto agli utili di Athenex?
Data	Compenso totale	Stipendio	Guadagni aziendali
Dec 31 2022	US$715k	US$525k	-US$98m
Sep 30 2022	n/a	n/a	-US$178m
Jun 30 2022	n/a	n/a	-US$192m
Mar 31 2022	n/a	n/a	-US$198m
Dec 31 2021	US$2m	US$525k	-US$158m
Sep 30 2021	n/a	n/a	-US$132m
Jun 30 2021	n/a	n/a	-US$135m
Mar 31 2021	n/a	n/a	-US$144m
Dec 31 2020	US$3m	US$161k	-US$142m
Sep 30 2020	n/a	n/a	-US$118m
Jun 30 2020	n/a	n/a	-US$116m
Mar 31 2020	n/a	n/a	-US$108m
Dec 31 2019	US$4m	US$519k	-US$123m
Sep 30 2019	n/a	n/a	-US$129m
Jun 30 2019	n/a	n/a	-US$141m
Mar 31 2019	n/a	n/a	-US$145m
Dec 31 2018	US$3m	US$500k	-US$117m
Sep 30 2018	n/a	n/a	-US$119m
Jun 30 2018	n/a	n/a	-US$96m
Mar 31 2018	n/a	n/a	-US$97m
Dec 31 2017	US$5m	US$500k	-US$131m
Sep 30 2017	n/a	n/a	-US$143m
Jun 30 2017	n/a	n/a	-US$144m
Mar 31 2017	n/a	n/a	-US$118m
Dec 31 2016	US$522k	US$200k	-US$88m

Compensazione vs Mercato: La retribuzione totale di Johnson ($USD 714.51K ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 681.57K ).

Compensazione vs guadagni: La retribuzione di Johnson è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Johnson Lau (63 yo)

12.8yrs

Mandato

US$714,505

Compensazione

Dr. Yiu-Nam Lau, also known as Johnson, MBBS, MD, FRCP, Ph D., has been the Chief Executive Officer of Athenex, Inc. since 2011. Dr. Lau is the Vice Chairman and CEO of Axis Therapeutics.Dr. Lau serves as...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Yiu-Nam Lau	Chairman & CEO	12.8yrs	US$714.51k	2.99% $ 3.9k
Jeffrey Yordon	COO & President of Athenex Pharmaceutical Division	6.7yrs	US$524.66k	0.14% $ 186.9
Daniel Lang	President of Athenex Cell Therapy	2.4yrs	US$481.15k	0.047% $ 62.0
Allen Barnett	Co-Founder & President Emeritus	12.8yrs	Nessun dato	Nessun dato
Steven Adams	Chief Accounting Officer	2.2yrs	US$289.28k	0.0018% $ 2.4
Caileigh Dougherty	Director of Investor Relations	no data	Nessun dato	Nessun dato
Jacqueline Li	Vice President of Alliance Management & Corporate Development	3.8yrs	Nessun dato	Nessun dato
John Matthei	Chief Human Resource Officer	no data	Nessun dato	Nessun dato
David Cutler	Deputy Chief Medical Officer of Biologics & Cell Therapy	3.8yrs	Nessun dato	Nessun dato
Timothy Cook	Chief Business & Commercial Officer of Proprietary Drugs	5.3yrs	Nessun dato	0.048% $ 62.9
Nicholas Campbell	Chief Restructuring Officer	less than a year	Nessun dato	Nessun dato
Li Shen	Vice President of Financial Planning & Treasury	6.8yrs	Nessun dato	Nessun dato

4.5yrs

Durata media

59yo

Età media

Gestione esperta: Il team dirigenziale di ATNX.Q è considerato esperto (durata media dell'incarico 4.5 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Yiu-Nam Lau	Chairman & CEO	19.9yrs	US$714.51k	2.99% $ 3.9k
John Vierling	Independent Director	4.5yrs	US$42.00k	0.14% $ 187.4
Jinn Wu	Independent Director	16.5yrs	US$40.86k	0.40% $ 529.0
Robert Jay Spiegel	Independent Director	3.2yrs	US$46.00k	0.053% $ 69.8
Kwan-Hung Tsang	Independent Director	5.3yrs	US$55.14k	0.20% $ 257.2
Jordan Kanfer	Independent Director	4.5yrs	US$42.00k	0.0099% $ 13.0
Manson Fok	Director	8.3yrs	US$35.71k	1.28% $ 1.7k
Stephanie Davis	Lead Independent Director	4.5yrs	US$46.00k	0.093% $ 121.8

4.9yrs

Durata media

64.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ATNX.Q sono considerati esperti (durata media dell'incarico 4.9 anni).

Athenex Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Athenex, Inc. Announces the Separation of Joe Annoni as Assistant Chief Restructuring Officer

Insufficient new directors

Athenex, Inc. Appoints Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy to Lead Its Clinical Development, Clinical Operations, and Regulatory Affairs Functions

Insufficient new directors

Insufficient new directors

Kim Campbell Not to Stand for Re-Election to the Athenex Board of Directors At the 2022 Annual Meeting of Stockholders

Recent updates

Athenex, Inc. Announces the Separation of Joe Annoni as Assistant Chief Restructuring Officer

Nasdaq to Delist the Common Stock of Athenex

Athenex, Inc.(OTCPK:ATNX.Q) dropped from NASDAQ Composite Index

Athenex, Inc. announced delayed 10-Q filing

Nasdaq Staff Determines Athenex's Common Stock to be Delisted from Nasdaq as a Result of the Chapter 11 Case

Athenex, Inc.(NasdaqGS:ATNX) dropped from S&P TMI Index

Motion for Asset Sale Filed by Athenex, Inc.

Athenex Receives Letter from the Listing Qualifications Staff of the Nasdaq as the Company No Longer Meets Nasdaq Listing Rule 5450(b)(3)(C)

Athenex Announces Reverse Stock Split

Athenex Announces MHRA Decision on Oral Paclitaxel

Athenex, Inc. Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer

Price target decreased to US$2.17

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Athenex Announces Receipt of Positive Nasdaq Listing Determination

Athenex, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Athenex Receives Written Notification from Nasdaq Stating the Company Had Not Regained Compliance with the Rule and Was Ineligible to Obtain A Second 180 Calendar Day Period to Regain Compliance

Athenex, Inc. has completed a Follow-on Equity Offering in the amount of $29.995333 million.

Athenex prices $30M in stock and warrants offering

Dr. Reddy's, Intas Reportedly in Talks to Buy Athenex

Athenex surges 70% as Dr Reddy's and Intas race to form buyout deal

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.33 loss in 2Q 2021)

Athenex GAAP EPS, revenue misses estimates

Athenex, Inc. to Report Q2, 2022 Results on Jul 28, 2022

TiHe Capital (Beijing) Co. Ltd. agreed to acquire Chongqing Taihao Pharmaceutical Co., Ltd. and Athenex Pharmaceuticals (Chongqing) Limited from Athenex, Inc. (NasdaqGS:ATNX) for CNY 124 million.

Athenex to sell its China API business for $19M

Athenex, Inc. Appoints Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy to Lead Its Clinical Development, Clinical Operations, and Regulatory Affairs Functions

Insufficient new directors

Athenex, Inc. Provides Sales Guidance for the Full Year 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Athenex, Inc. to Report Q1, 2022 Results on May 10, 2022

Price target decreased to US$4.50

Athenex Presents Interim Data from Phase 1 ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at the 2022 Transplantation & Cellular Meetings of ASTCT and CIBMTR

Kim Campbell Not to Stand for Re-Election to the Athenex Board of Directors At the 2022 Annual Meeting of Stockholders

Price target decreased to US$4.50

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$5.50

Price target increased to US$6.67

Athenex Announces Appoints Joe Annoni as Chief Financial Officer

ImmunityBio, Inc. (NasdaqGS:IBRX) completed the acquisition of Dunkirk Manufacturing Facility and Certain Related Assets of Athenex, Inc. (NasdaqGS:ATNX).

Athenex, Inc. Announces UK MHRA Validation of the Marketing Authorization Application for Oral Paclitaxel and Encequidar for Review

Athenex to Present Subgroup Analysis from Phase 3 Study of Oral Paclitaxel Plus Encequidar (KX-ORAX-001) in Metastatic Breast Cancer At SABCS 2021

Independent Director recently bought US$61k worth of stock

Third quarter 2021 earnings released: US$0.33 loss per share (vs US$0.44 loss in 3Q 2020)

Independent Director recently bought US$161k worth of stock

Athenex: Is This Stock A Buy, Sell, Or Hold? It's A Hold.

Chief Financial Officer Randoll Sze has left the company

Second quarter 2021 earnings released: US$0.33 loss per share (vs US$0.50 loss in 2Q 2020)

Consensus EPS estimates fall to -US$1.31

Price target decreased to US$7.50

Athenex, Inc. Presents Data on Oral Docetaxel and Oral Paclitaxel at ASCO2021 Virtual Scientific Program

Athenex, Inc. Announces Klisyri® (Tirbanibulin) Receives Positive Chmp Opinion from the European Medicines Agency (Ema) for the Treatment of Actinic Keratosis of the Face or Scalp

Athenex, Texas Children’s Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine Present New Clinical Data on GD2 CAR-NKTCells in Neuroblastoma at ASGCT Annual Meeting

First quarter 2021 earnings released: US$0.27 loss per share (vs US$0.24 loss in 1Q 2020)

Independent Director exercised options to buy US$230k worth of stock.

Consensus EPS estimates increase to -US$1.42

Athenex, Inc. Reaffirms Sales Guidance for the Year 2021

Athenex, Inc. (NasdaqGS:ATNX) acquired Kuur Therapeutics Limited.

Athenex EPS beats by $0.13, beats on revenue

Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against Athenex, Inc

Is Athenex (NASDAQ:ATNX) Weighed On By Its Debt Load?

Robbins LLP Reminds Shareholders that Athenex, Inc. is Being Sued for Misleading Shareholders

Chairman & CEO exercised options to buy US$98k worth of stock.

Insider recently sold US$1.9m worth of stock

Have Insiders Sold Athenex, Inc. (NASDAQ:ATNX) Shares Recently?

Analysts lower revenue estimates to US$115.2m

These Analysts Just Made A Sizeable Downgrade To Their Athenex, Inc. (NASDAQ:ATNX) EPS Forecasts